Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of.
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin
NAARDEN, the Netherlands and MIAMI, April 01, 2024 NewAmsterdam Pharma Company N.V. , a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk.